The department supports investigator-led research through a series of well-founded laboratories. This research covers every aspect of biological science related to medicine: from the bench to the bedside, from blue sky to full clinical trials, from technology development to spin-out. It covers many fields and many clinical disciplines.
The department supports this research in an environment designed to foster the long-term career development of fellows and research staff.
All of the above is made possible through the generosity and long-term support of our sponsors and funders.
199 patients received standard care, of which 99 received lopinavir-ritonavir for 14 days. Lopinavir-ritonavir didn’t induce significant clinical improvement, and mortality was similar in both groups. However, patients treated with lopinavir-ritonavir spent less time in hospital and in intensive care. The trial enrolled severely ill patients and was not big enough to detect modest benefits. Much larger studies are warranted to confirm or exclude if lopinavir-ritonavir treatment can help.
A specialist technique used to study drugs has been completed for the first time during an outbreak of Ebola virus disease. This study used pharmacokinetics – the measurement of the change in drug concentration in a person over time – to study an experimental drug for the treatment of Ebola virus disease during the 2015 outbreak in Sierra Leone.